Could a vaccine given during pregnancy shield infants from a deadly virus?
NCT ID NCT06325657
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests an RSV vaccine in pregnant women living with HIV. The goal is to see if the vaccine is safe and helps mothers pass protective antibodies to their babies, potentially preventing severe RSV lung infections in infants. The trial involves about 681 pregnant participants and follows both mothers and their babies for up to 6 months after birth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSVpreF vaccine
What this could lead to
If successful, this vaccine could help protect infants born to mothers with HIV from severe RSV infections, potentially reducing hospitalizations and deaths.
What could go wrong
This is a phase 3 trial, but results may not confirm full protection or safety for all. The vaccine may cause side effects or not generate enough immunity in this specific population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Foscenvivint for Liver Cirrhosis in HIV/HCV & He NCT07681089
- Smoking Cessation App for Black Smokers with HIV NCT05709002
- #TranscendentHealth: Text program for trans yout NCT07681908
- HIV and Cerebral Small Vessel Disease Study NCT02210130
- Urine HPV Test for Cervical Cancer Screening (NCT05413798)
- Cervical Cancer Screening in Ethiopia: HPV Self- NCT07678047
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Botho Ke Bontle Health Services
Pretoria, Gauteng, 0184, South Africa
-
FAMCRU - Worcester
Worcester, Western Cape, 6850, South Africa
-
Gole Biomed Research Centre
Polokwane, Limpopo, 0699, South Africa
-
Gugulethu Green Clinic
Cape Town, Western Cape, 7750, South Africa
-
Josha Research
Bloemfontein, Free State, 9301, South Africa
-
MRC Unit on Child And Adolescent Health
Cape Town, Western Cape, 7700, South Africa
-
Qhakaza Mbokodo Research Clinic
Ladysmith, KwaZulu-Natal, 3370, South Africa
-
REIMED Reiger Park
Boksburg, Gauteng, 1459, South Africa
-
Setshaba Research Centre
Pretoria, Gauteng, 0152, South Africa
-
Synergy Biomed Research Institute
East London, Eastern Cape, 5241, South Africa
-
University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA)
Johannesburg, Gauteng, 2013, South Africa
-
Wits RHI
Johannesburg, Gauteng, 2001, South Africa
-
Wits VIDA Nkanyezi Research Unit
Johannesburg, Gauteng, 2093, South Africa
-
Worthwhile Clinical Trials
Benoni, Gauteng, 1500, South Africa